【再鼎医药:repotrectinib在台湾地区获批双适应证】3月3日,再鼎医药宣布,中国台湾地区药品审评机构已批准repotrectinib的新药上市申请,用于治疗:ROS1阳性之局部晚期或转移性非小细胞肺癌的成人患者,NTRK基因融合阳性之实体肿瘤的成人患者。

金融界
03 Mar
3月3日,再鼎医药宣布,中国台湾地区药品审评机构已批准repotrectinib的新药上市申请,用于治疗:ROS1阳性之局部晚期或转移性非小细胞肺癌的成人患者,NTRK基因融合阳性之实体肿瘤的成人患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10